TITLE

Intravitreal Bevacizumab Following Laser Therapy for Severe Retinopathy of Prematurity

AUTHOR(S)
Erol, Nazmiye; Gürsoy, Hüseyin; Sahin, Afsun; Basmak, Hikmet
PUB. DATE
July 2010
SOURCE
Journal of Pediatric Ophthalmology & Strabismus;Jul/Aug2010, Vol. 47 Issue 4, pe1
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
Trial of intravitreal bevacizumab injection in 7 eyes of 4 infants with continued retinopathy of prematurity progression despite previous laser therapy was reported. Six of the eyes benefited from the therapy. Intravitreal bevacizumab injection may be an alternative therapy in progressive stage 3 retinopathy of prematurity despite laser photocoagulation.
ACCESSION #
61063158

 

Related Articles

  • Anti-VEGFs may be viable option in treating retinopathy of prematurity. Cimberle, Michela // Ocular Surgery News Europe;Feb2010, Vol. 21 Issue 2, p14 

    The article focuses on the viability of an anti-vascular endothelium growth factor (VEGF) treatment for the therapy of patients with retinopathy of prematurity, according to Doctor Georges Caputo.

  • Prevention of retinopathy of prematurity. FORTES FILHO, JOÃO BORGES; ECKERT, GABRIELA UNCHALO; TARTARELLA, MARCIA BEATRIZ; PROCIANOY, RENATO SOIBELMANN // Arquivos Brasileiros de Oftalmologia;2011, Vol. 74 Issue 3, p217 

    Retinopathy of prematurity (ROP) is related to oxygen-regulated vascular endothelial growth factor and to insulin-like growth factor-I. After premature birth, supplemental oxygen induces a retinal hyperoxic condition with vasoconstriction and to a definitive interruption of retinal...

  • An unusual case of retinopathy of prematurity. Mandal, K.; Drury, J. A.; Clark, D. I. // Journal of Perinatology;May2007, Vol. 27 Issue 5, p315 

    Aims:Stage 3 retinopathy of prematurity (ROP) usually develops in the very small babies. An infant born at 30 (2) weeks' gestation and of birth weight 2102 g was found to have stage 3 ROP bilaterally. The unusual severity of the disease in a child of birth weight >2000 g prompted further...

  • Anti-VEGF therapy is on the horizon for APROP. Capone Jr., Antonio // Ophthalmology Times;9/1/2008, Vol. 33 Issue 17, p64 

    The article reports that anti-vascular endothelial growth factor (VEGF) therapy is on the horizon for aggressive posterior retinopathy of prematurity (APROP). Oakland University clinical associate professor of ophthalmology, Dr. Antonio Capone Jr. depicted that anti-APROP may be a feasible...

  • The Optic UK Lecture: bench-to-bedside adventures of a diabetes researcher: results past, results present. Frank, R. N. // Eye;Mar2011, Vol. 25 Issue 3, p331 

    This presentation covers two topics. First is a basic laboratory study, designed to explore the mechanism for the phenomenon of 'early worsening,' in which individuals with type 1 diabetes and early to moderate retinopathy are rapidly placed on 'tight' blood glucose control, after which about...

  • Anti-VEGF for ROP may still be in its infancy. Charters, Lynda; Trese, Michael T. // Ophthalmology Times;4/1/2013, Vol. 38 Issue 7, p40 

    The article focuses on the use of anti-vascular endothelial growth factor (VEGF) drugs, which may not be ready for retinopathy of prematurity (ROP) treatment. Doctor Michael T. Trese says that laser is the standard treatment for infants with ROP because the efficacy and safety of anti-VEGF drugs...

  • Infantile hemangiomas and retinopathy of prematurity: clues to the regulation of vasculogenesis. Hyland, Rachael; Komlósi, Katalin; Alleman, Brandon; Tolnai, Marina; Wood, Laura; Bell, Edward; Ertl, Tibor // European Journal of Pediatrics;Jun2013, Vol. 172 Issue 6, p803 

    Retinopathy of prematurity (ROP) and infantile hemangiomas are vascular disorders that may share common mechanisms. This study examined a potential clinical association between these disorders in populations of preterm infants at two hospitals in the USA and Hungary. Clinically collected data...

  • Anti-VEGF therapy for ROP requires further study. Krader, Cheryl Guttinan // Ophthalmology Times;4/15/2013, Vol. 38 Issue 8, p30 

    The article reports that anti-vascular endothelial growth factor (VEGF) therapy for severe retinopathy of prematurity (ROP) needs further study. Professor of ophthalmology Dr. Graham E. Quinn of University of Pennsylvania noted that the study Bevacizumab Eliminates the Angiogenic Threat of...

  • Anti-VEGF drugs: Not just for retinal pathologies alone. Charters, Lynda // Formulary;Mar2013, Vol. 48 Issue 3, p121 

    The article discusses a presentation which physician Cynthia G. Martox gave during Glaucoma Subspecialty Day at the 2013 annual meeting of the American Academy of Ophthalmology. In the presentation Martox discussed the ways in which anti-vascular endothelial growth factor drugs can be used with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics